StreetAlpha.app
Home › Stocks › RNA

Atrium Therapeutics, Inc. (RNA)

$6.92
▼ −0.86%
LAST CLOSE · NOV 20

Atrium Therapeutics, Inc. (RNA) tracked by StreetAlpha. It last closed at $6.92 on Nov 20, down 0.86% on the day. The next earnings report for RNA is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, RNA reported EPS of -$0.25. Over its last 3 reports the stock moved an average of 1.5% the session after earnings. Over the last 12 months RNA insiders bought $0 of stock on the open market and sold $4.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is RNA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RNA.
Next report
Feb 11
Estimated date · After the close
Reported EPS
-$0.25
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How RNA moved after its last 3 reports
Average move the session after a report ±1.5%
Nov 12, 2026After the close+0.1%
Aug 13, 2026After the close+4.1%
May 14, 2026After the close−0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RNAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RNA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RNA

Technical Analysis

RNA · as of the Nov 20 close · updated each morning
Falling, nearing oversold

The stock is 13% below its 20 day and 18% below its 50 day average. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $6.72, and the nearest resistance the Pivot at $7.08.

Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.7%/day
Key levels
$16.7752 week high+142.3%
$10.34100 day average+49.4%
$8.32Swing high (Oct 21)+20.2%
$8.1850 day average+18.2%
$7.8520 day average+13.4%
$7.28Pivot R1+5.2%
$7.08Pivot+2.3%
$6.92Last close
$6.72Pivot S1−2.9%
$6.3652 week low−8.1%
$6.36Swing low (Nov 16)−8.1%
Indicators
RSI (14)34.34Weak, oversold below 30Neutral
MACD-0.48Below its signal lineBearish
Stochastic18.5Near the bottom of its rangeOversold
ADX (14)27.9Trending down
Williams %R-78.7Oversold below −80, overbought above −20Neutral
CCI (20)-91.3Oversold below −100, overbought above 100Neutral
Rate of change−17.0%Change over 10 sessionsBearish
ATR (14)$0.46Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for RNA

What happened before

See how RNA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for RNAHow many large options trades hit RNA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RNA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●76 buying vs 75 selling
  • ▼Held by funds -9.5 pts
  • ▼Funds holding -8
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding148156−5.1%
In funds' top 1012−50.0%
Held by funds65.1%74.6%−9.5 pts
New / increased26 / 5037 / 47−9.5%
Reduced / sold out40 / 3535 / 47−8.5%
Put/call ratio4.860.32+1430.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RNA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.2M13 sales · 8 insiders
100% of the selling was under pre-arranged trading plans.
2026-01 sold $4.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 21Teresa McCarthyChief Human Resources OfficerSale plan2,929$72.45$212K
Jan 21Arthur A LevinDirectorSale plan1,758$72.45$127K
Jan 21Michael F MacLeanCFOSale plan4,542$72.45$329K
Jan 21W. Michael FlanaganChief Scientific OfficerSale plan6,534$72.45$473K
Jan 21Sarah BoycePresident and CEOSale plan14,387$72.45$1.0M
Jan 21Steven George HughesChief Medical OfficerSale plan4,895$72.45$355K
Every insider buy and sale for RNA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RNA insider trades →

From SEC Form 4 filings by RNA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNA is in one of them and how their past RNA trades turned out.

RNA in the AI portfolios
Loading…

RNA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNA in an article yet. Here's the latest on the wider market.

RNA in the news